https://www.selleckchem.com/pr....oducts/ins018-055-is
P1NP and 25-hydroxy vitamin D levels at baseline were identified as potential predictors of development of acute-phase reactions. The combination therapy of Zol or DMAb and ELD may increase BMD at 12months after the first administration in Japanese patients with postmenopausal osteoporosis, regardless of BPs pretreatment. Bone metabolic markers at baseline may be useful predictors for reaction to the therapy and side effects caused by these combination therapies in postmenopausal osteoporosis. The combination therapy of Zo
Like
Comment
Share
